fulvestrant has been researched along with Invasiveness, Neoplasm in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Durando, M; Gastiazoro, MP; Lorenz, V; Milesi, MM; Varayoud, J; Vollmer, G; Zierau, O | 1 |
| Ai, B; Cao, X; Fan, S; Li, D; Li, L; Liao, Y; Qiu, W | 1 |
| Glasgow, M; Murugan, P; Rivard, C; Song, M | 1 |
| Duraki, D; Helferich, WG; Huang, R; Kim, JE; Mao, C; Nelson, ER; Park, BH; Shapiro, DJ; Wang, L; Yu, L | 1 |
| Bartsch, JW; Carl, B; Hannen, R; Nimsky, C; Steffani, M; Voellger, B; Wang, J | 1 |
| Barry, WT; Burstein, HJ; Come, SE; DeMichele, A; Guo, H; Huang Bartlett, C; Jeselsohn, R; Koehler, M; Mayer, EL; Miller, K; Mulvey, T; Overmoyer, B; Rugo, HS; Waks, AG; Winer, EP | 1 |
| Felty, Q; Okoh, VO; Parkash, J; Poppiti, R; Roy, D | 1 |
| Balatti, V; Byrd, JC; Cascione, L; Consiglio, J; Coppola, V; Croce, CM; De Luca, L; Freitas, MA; Gasparini, P; Guan, J; Hofmeister, CC; Lagana, A; Marcucci, G; Nuovo, G; Palmieri, D; Pichiorri, F; Piovan, C; Rocci, A; Shapiro, CL; Talabere, T; Volinia, S; You, J | 1 |
| Giannopoulou, E; Kalofonos, HP; Koutras, AK; Lymperatou, D | 1 |
| Chang, WC; Chang, YY; Chen, LC; Chen, LM; Chung, WM; Hung, YC; Lin, TY; Ma, WL; Wu, LY | 1 |
| Chan, QK; Ho, SM; Lau, KM; Leung, YK; Ma, FM; Maranchie, J; Ng, CF; To, KF; Tse, HM | 1 |
| Harding, E | 1 |
| Cao, L; Gao, H; Gu, Y; Liu, C; Liu, Q; Shan, X; Wang, H; Xue, Y; Zhang, Y | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Aleskandarany, M; Ball, G; Douglas Macmillan, R; Ellis, IO; Gee, JM; Green, AR; Habashy, HO; Nicholson, RI; Paish, EC; Powe, DG; Rakha, EA; Staka, CM | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Grandison, PM; Kang, J; Kannan, N; Kong, X; Liu, DX; Liu, ET; Lobie, PE; Mertani, HC; Miller, LD; Mohankumar, KM; Perry, JK; Tang, J; Zhu, T | 1 |
| Du, X; Mayer, D; Miao, L; Shi, J; Wang, CY; Yu, L; Zhang, J | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Brennan, DJ; Crown, JP; Gallagher, WM; Gremel, G; Higgins, DG; Jirström, K; Madden, SF; Martin, F; McGee, SF; McNally, S; Mulrane, L; O'Connor, DP | 1 |
| Bogart, DF; Castañeda, JM; Li, P; Lupu, R; Tsai, MS | 1 |
| Bracke, M; Derycke, L; Mareel, M; Milanezi, F; Paredes, J; Schmitt, F; Stove, C; Stove, V; Van Marck, V | 1 |
| Garber, J; Heulings, R; Lareef, MH; Russo, IH; Russo, J; Russo, PA | 1 |
| Harper, M; Hiscox, S; Jiang, W; Jordan, NJ; McClelland, R; Nicholson, RI; Smith, C | 1 |
| Cathiard, AM; Chambon, M; Garcia, M; Maynadier, M; Nirdé, P; Platet, N; Ramirez, JM | 1 |
| Brémaud, J; Hameau, MC; Magnien, V; Nique, F; Philibert, D; Planchon, P; Prévost, G; Teutsch, G; Van de Velde, P | 1 |
| Dewhurst, LO; Gee, JW; MacNeil, S; Rennie, IG | 1 |
| Couissi, D; Dubois, V; Remacle, C; Schonne, E; Trouet, A | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Hurt, GM; Mathew, AC; Pento, JT; Rajah, TT | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| DePasquale, JA | 1 |
| Pento, JT; Rajah, TT | 1 |
| De Arment, R; Demers, L; Fischer, S; Franks, M; Griffith, J; Leiby, B; Manni, A; Mauger, D; Verderame, M; Washington, S | 1 |
| Bogart, DF; Li, P; Lupu, R; Mehmi, I; Tsai, MS | 1 |
1 review(s) available for fulvestrant and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
3 trial(s) available for fulvestrant and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Feasibility Studies; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Palbociclib for hormone receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Piperazines; Postmenopause; Premenopause; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2015 |
32 other study(ies) available for fulvestrant and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Glyphosate induces epithelial mesenchymal transition-related changes in human endometrial Ishikawa cells via estrogen receptor pathway.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Survival; Down-Regulation; Endometrium; Epithelial-Mesenchymal Transition; Female; Fulvestrant; Glycine; Glyphosate; Humans; Neoplasm Invasiveness; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2020 |
Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Movement; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Sulfonamides; Toll-Like Receptor 4 | 2020 |
Aggressive Angiomyxoma of the Vulva and Bladder.
Topics: Antineoplastic Agents, Hormonal; Diagnosis, Differential; Estradiol; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Myxoma; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vulvar Neoplasms | 2017 |
Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Neoplasm Invasiveness; Proto-Oncogene Proteins c-myc; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study.
Topics: Adenoma; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Estrogen Receptor Antagonists; Fulvestrant; Humans; Neoplasm Invasiveness; Pituitary Neoplasms; Selective Estrogen Receptor Modulators | 2019 |
Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells.
Topics: Animals; Azoles; Catalase; Catechols; Cell Cycle Proteins; Cell Proliferation; Cell Transformation, Neoplastic; Collagen; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Epithelial Cells; Estradiol; Estrogens, Catechol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Isoindoles; Mammary Glands, Human; Mice; Models, Biological; Neoplasm Invasiveness; Organoselenium Compounds; Oxidation-Reduction; Phenotype; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Spheroids, Cellular | 2013 |
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Genes, Neoplasm; Guanine; HEK293 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; RNA-Binding Proteins; Transcription, Genetic; Up-Regulation | 2013 |
The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen | 2013 |
Non-genomic estrogen/estrogen receptor α promotes cellular malignancy of immature ovarian teratoma in vitro.
Topics: Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Ovarian Neoplasms; Phosphorylation; Teratoma; Tissue Culture Techniques; Tumor Stem Cell Assay | 2014 |
Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Fulvestrant; HMGA Proteins; Humans; Male; MicroRNAs; Neoplasm Invasiveness; Prostatic Neoplasms; Up-Regulation | 2014 |
ESR1 and its antagonist fulvestrant in pituitary adenomas.
Topics: Adenoma; Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cohort Studies; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Invasiveness; Nitriles; Pituitary Neoplasms; Rats, Inbred F344; Signal Transduction; Young Adult | 2017 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Topics: Adult; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Estradiol; Female; Flavonoids; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Mitogen-Activated Protein Kinases; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Transferrin; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; RNA, Messenger; Tamoxifen; Time Factors; Tissue Array Analysis; Transferrin; Treatment Outcome | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; Neoplasm Invasiveness; Peptides; Prognosis; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Survival Rate; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-3 | 2010 |
Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells.
Topics: Cell Line, Tumor; Culture Media, Conditioned; Estradiol; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Paracrine Communication; Prostate; Prostatic Neoplasms; Receptors, Estradiol; Stromal Cells; Time Factors; Transforming Growth Factor beta1 | 2011 |
miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Movement; Cell Survival; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; MCF-7 Cells; MicroRNAs; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Tamoxifen; Tissue Array Analysis; Transcriptome; Treatment Outcome | 2012 |
Cyr61 promotes breast tumorigenesis and cancer progression.
Topics: Adenocarcinoma; Breast Neoplasms; Collagen; Cysteine-Rich Protein 61; Disease Progression; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Endothelial Growth Factors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Laminin; Lymphokines; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteoglycans; Receptors, Estrogen; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells.
Topics: Base Sequence; Breast Neoplasms; Cadherins; Cell Adhesion; DNA Primers; DNA, Complementary; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2004 |
The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-beta-estradiol and 4-OH estradiol in human breast epithelial cells.
Topics: Agar; Breast; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogens; Estrogens, Catechol; Female; Flow Cytometry; Fulvestrant; G1 Phase; Humans; Laminin; Neoplasm Invasiveness; Phenotype; Proteoglycans; Resting Phase, Cell Cycle | 2005 |
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Fibroblasts; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-met; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Up-Regulation; Wound Healing | 2006 |
Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Transcription, Genetic; Tumor Cells, Cultured; Zinc Fingers | 2008 |
RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinogenicity Tests; Cell Cycle; Cell Division; Chick Embryo; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, ras; Heart; Humans; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Myocardium; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1996 |
Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Estradiol; Fibronectins; Fulvestrant; Humans; Melanoma; Naphthalenes; Neoplasm Invasiveness; Receptors, Progesterone; Skin Neoplasms; Sulfonamides; Tamoxifen; Uveal Neoplasms | 1997 |
Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.
Topics: Acids; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cathepsin D; Culture Media, Serum-Free; Enzyme Activation; Enzyme Precursors; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunoblotting; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1997 |
Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.
Topics: Breast Neoplasms; Cell Movement; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1997 |
Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Collagenases; Electrophoresis, Polyacrylamide Gel; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Glycoproteins; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Protease Inhibitors; Receptors, Estrogen; Tamoxifen; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1997 |
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibronectins; Fulvestrant; Humans; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |
Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells.
Topics: Actins; Breast Neoplasms; Cadherins; Cell Movement; Cytoskeleton; Estradiol; Estrogen Antagonists; Fluorescent Antibody Technique; Fulvestrant; Humans; Microscopy, Video; Neoplasm Invasiveness; Neoplasm Metastasis; Tumor Cells, Cultured | 1999 |
Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Basement Membrane; Breast Neoplasms; Cell Adhesion; Collagen; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Laminin; Microscopy, Electron, Scanning; Microvilli; Neoplasm Invasiveness; Neoplasm Metastasis; Proteoglycans; Pseudopodia; Tamoxifen; Tumor Cells, Cultured | 1999 |
S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells.
Topics: Adenosylmethionine Decarboxylase; Agar; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Collagen; DNA-Binding Proteins; Drug Combinations; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Proteoglycans; Sensitivity and Specificity; STAT3 Transcription Factor; Tamoxifen; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Expression and regulation of Cyr61 in human breast cancer cell lines.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Breast Neoplasms; Calcitriol; Cysteine-Rich Protein 61; Drug Resistance; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Immediate-Early; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Protein Structure, Tertiary; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tetradecanoylphorbol Acetate; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |